Navigation Links
Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion
Date:7/27/2011

ard-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our strategic initiatives, our business and investment plans in China, the market for our products in China and our share of that market, our financial performance in China and other emerging markets, new product launches and launch cadence, regulatory approvals, clinical trials (including clinical trial plans in emerging markets), product performance, training programs and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, political, environmental, competitive, reimbursement, legal and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. 
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... Mass. , July 10, 2014 Decision ... report awareness of the U.S. Food and Drug Administration,s ... new phosphate binder Velphoro, which was approved by the ... in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... The Medical Oncology Association of Southern California ... an agreement to work together to expand use ... costs of cancer care in Southern California. ... and distribution services to help health care professionals, ...
... The American Society of Bariatric Physicians (ASBP) is sad ... go out to his family, friends and fans.  The recent ... a contributing factor to his death are concerning and bring ... prescribed. While the specific details of Bubba ...
Cached Medicine Technology:Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 2Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 3Physicians Who Treat Obesity Respond to the News of Bubba Smith's Overdose 2
(Date:7/11/2014)... repaired knee Anterior Cruciate Ligament (ACL) happens all too ... the American Orthopaedic Society for Sports Medicine,s (AOSSM) Annual ... risk factors may minimize the chance of a future ... few risk factors such as, age, activity level and ... of re-injury," said lead author, Christopher C. Kaeding, MD ...
(Date:7/11/2014)... July 11, 2014 With the maturity ... requirements on comfort, the installation rate of Chinese car ... the installation rate exceeded 88% and the demand outnumbered ... the next few years, Chinese car electric window regulator ... 2017, the market size is expected to exceed 110 ...
(Date:7/11/2014)... Wild by Nature, a natural and organic supermarket ... opening a fifth store to be located in West Islip, ... the largest selections of wheat and gluten-free products available. With ... stores have become a one-stop shop for anyone who needs ... gluten intolerance, is a spectrum of disorders, including celiac disease, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 B. E. Smith, ... providers, has been retained to lead a national chief ... in Bend, Ore. The top executive search firm ... placed more than 900 healthcare executives into organizations. , ... St. Charles Health System is the largest provider of medical ...
(Date:7/11/2014)... the experienced dressmaker in the world, has become one ... to beach wedding dresses . Recently, the firm ... in its online shop. Included in the new range ... has been considered as one of the best garment ... spokesman, BellasDress provides superb special occasion gowns and great ...
Breaking Medicine News(10 mins):Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 2Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 3Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 4Health News:Wild by Nature Opens New Location 2Health News:St. Charles Health System Retains B. E. Smith to Recruit New CNO 2Health News:St. Charles Health System Retains B. E. Smith to Recruit New CNO 3Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2
... to treat kidney cancer also targets a genetic mutation active ... (AML), the most common and lethal form of adult leukemia, ... Center report in the Jan. 29 edition of the Journal ... clinical trial, the drug sorafenib reduced the median percentage of ...
... Enforce PROTONIX Patent -, MADISON, N.J., Jan. 29 ... Nycomed, today announced the U.S. launch of Wyeth,s,own generic ... of generic pantoprazole tablets in the U.S. by Teva ... version of PROTONIX,will be distributed by Prasco starting today., ...
... Funding for Bioscience Summer Internship Program Over ... ... Foundation today,awarded $6.5 million to the Translational Genomics Research Institute,(TGen) as ... TGen for the next 25 years. The program helps cultivate new,scientific ...
... 29 At an Election Day,candidate forum in Tampa, ... Mitt Romney told a crowd of the,organization,s conservative seniors ... Hillarycare is not the answer., "I am convinced ... issue and,get our citizens insured but do it in ...
... Nektar,Therapeutics, (Nasdaq: NKTR ) President and Chief ... the upcoming Merrill Lynch,Pharmaceutical, Biotechnology & Medical Device Conference ... on Tuesday, February 5, 2008 at 1:00 p.m.,ET., ... a live,audio-only Webcast through a link posted on the ...
... Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ... it will be participating in Merrill Lynch,s 19th ... New York on,February 5, 2008, at 8:00 a.m. ... presentation can be accessed via Zimmer,s,Investor Relations website ...
Cached Medicine News:Health News:Kidney cancer drug attacks a major type of acute myeloid leukemia 2Health News:Kidney cancer drug attacks a major type of acute myeloid leukemia 3Health News:Wyeth Announces Launch of Own Generic Version of PROTONIX 2Health News:Wyeth Announces Launch of Own Generic Version of PROTONIX 3Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 2Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 3Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 4
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
BD Beaver Chondroplastic blade, sharp on two sides, curved, sterile...
BD Beaver Meniscus blade, 7 mm flat (4/bx, 1 bx/ca), specially designed maximum leverage and visibility, cutting edge: 7 mm, sterile....
... accurate testing of large oculomotor ... Fits all standard trial frames. ... of thin optical quality acrylic ... includes a display box. Available ...
Medicine Products: